Valneva SE VALN announced topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
- The trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses on Day 29 after vaccination.
- Lot-to-lot trials demonstrate manufacturing consistency, one of the standard requirements for vaccine licensure.
- Related: Valneva's Chikungunya Vaccine Candidate Shows Protective Neutralizing Antibodies In Late-Stage Trial.
- The trial, which included 408 participants aged 18 to 45 years, confirmed the favorable immunogenicity profile demonstrated in the pivotal Phase 3 trial.
- All three lots were equally well-tolerated, and the safety profile was consistent with the pivotal Phase 3 trial results.
- The lot-to-lot data will be part of its submission with the FDA expected to start in 2022.
- The lot-to-lot trial will continue towards the final six-month analysis, with final trial results expected in Q2 of 2022.
- Chikungunya is a mosquito-borne viral disease.
- VLA1553 is a live-attenuated, single-dose vaccine candidate targeting the chikungunya virus. It has been designed by deleting a part of the chikungunya virus genome.
- Price Action: VALN shares are closed at $57.39 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in